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ABSTRACT
Background Brace effectiveness for knee osteoarthritis 
(OA) remains unclear and international guidelines offer 
conflicting recommendations. Our trial will determine 
the clinical and cost- effectiveness of adding knee 
bracing (matched to patients’ clinical and radiographic 
presentation and with adherence support) to a package 
of advice, written information and exercise instruction 
delivered by physiotherapists.
Methods and analysis A multicentre, pragmatic, two- 
parallel group, single- blind, superiority, randomised 
controlled trial with internal pilot and nested qualitative 
study. 434 eligible participants with symptomatic knee OA 
identified from general practice, physiotherapy referrals 
and self- referral will be randomised 1:1 to advice, written 
information and exercise instruction and knee brace 
versus advice, written information and exercise instruction 
alone. The primary analysis will be intention- to- treat 
comparing treatment arms on the primary outcome (Knee 
Osteoarthritis Outcomes Score (KOOS)-5) (composite 
knee score) at the primary endpoint (6 months) adjusted 
for prespecified covariates. Secondary analysis of KOOS 
subscales (pain, other symptoms, activities of daily living, 
function in sport and recreation, knee- related quality of 
life), self- reported pain, instability (buckling), treatment 
response, physical activity, social participation, self- 
efficacy and treatment acceptability will occur at 3, 6, and 
12 months postrandomisation. Analysis of covariance and 
logistic regression will model continuous and dichotomous 
outcomes, respectively. Treatment effect estimates will 
be presented as mean differences or ORs with 95% CIs. 
Economic evaluation will estimate cost- effectiveness. 
Semistructured interviews to explore acceptability and 
experiences of trial interventions will be conducted with 
participants and physiotherapists delivering interventions.
Ethics and dissemination North West Preston Research 
Ethics Committee, the Health Research Authority and 
Health and Care Research in Wales approved the 
study (REC Reference: 19/NW/0183; IRAS Reference: 
247370). This protocol has been coproduced with 
stakeholders including patients and public. Findings will be 
disseminated to patients and a range of stakeholders.
Trial registration number ISRCTN28555470.
INTRODUCTION
Symptomatic knee osteoarthritis (OA) affects 
an estimated 10% of adults aged over 55 
years1 and has a significant impact on popula-
tion health, healthcare demand and societal 
costs. Trends in disability- adjusted life- years 
attributed to OA,2 the number and rate of 
Strengths and limitations of this study
 ► Large, publicly funded trial addressing an important 
unresolved question around affordable, effective 
non- pharmacological management of painful knee 
osteoarthritis.
 ► Recruitment from a broad range of settings (gener-
al practice, physiotherapy services and self- referral 
following awareness raising).
 ► The intervention arm of our pragmatic design 
stratifies the provision of brace type based on 
predominant clinical and radiographic features at 
presentation, incorporates adherence support com-
ponents and is delivered by physiotherapists—a 
scalable model for future implementation.
 ► Restricted range of off- the- shelf brace options 
included.
 ► The trial is powered for the overall comparison be-
tween treatment arms but not for subgroup analyses 
of different brace types.
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primary knee replacements,3–6 and rates of new presenta-
tions to primary care7 all suggest an increasingly common 
problem that accounts for up to 0.5% gross domestic 
product in high- income countries.8 9
In the UK, the National Institute for Health and Care 
Excellence (NICE) currently recommends that people 
with OA who have ‘biomechanical joint pain with or 
without instability should be considered for assessment 
for bracing as an adjunct to their core treatments’.10 
However, there remains a lack of high- quality trials on 
their clinical and cost- effectiveness. While some inter-
national clinical guidance recommend bracing for knee 
OA,11 12 several others have been unable to make a recom-
mendation due to the limited evidence base.13–16
A Cochrane review, originally published in 200517 and 
updated in 2015,18 identified five randomised controlled 
trials (RCTs),19–23 with sample sizes ranging from 33 to 
117, that compared a type of brace for OA of the knee 
versus no treatment or other treatment such as restricted 
activity, patient education, exercise, pharmacological 
treatment and orthoses or surgical treatment. The review 
concluded that ‘low- quality evidence suggests that people 
with OA who use a knee brace may have little or no reduc-
tion in pain or improvements in knee function and quality 
of life’. Since then, five further systematic reviews16 24–27 
and one narrative review28 have been published and iden-
tified a total of 13 RCTs,29–41 (two RCTs were published 
after the Cochrane review).40 41 These concluded that 
either the existing evidence is insufficient,16 26 27 or is 
consistent with small- to- moderate effects on pain and 
function for unloader braces24 and soft sleeve braces25; 
therefore, further investigation is warranted. Only three 
trials20 21 29 and one observational study42 followed partic-
ipants up for 6 months or longer.
The current trial was designed in response to a 
commissioned call from the National Institute for Health 
Research Health Technology Assessment programme for 
an efficient and pragmatic trial to investigate, in primary 
care, the clinical and cost- effectiveness of knee braces in 
the management of knee OA.
OBJECTIVES
The overall aim of the ‘PROvision of braces for Patients 
with knee OA’ (PROP OA) trial is to determine the clinical 
and cost- effectiveness of adding knee bracing (matched 
to patients’ clinical and radiographic presentation and 
with adherence support) to advice, written information 
and exercise instruction compared with advice, written 
information and exercise instruction alone, in adults with 
symptomatic knee OA.
Specifically, our primary objective is to determine, in 
adults with symptomatic knee OA, if the advice, written 
information and exercise instruction plus knee brace 
is superior to advice, written information and exercise 
instruction alone for Knee Osteoarthritis Outcomes 
Score (KOOS)-5, a composite score of patient- reported 
pain, other symptoms, activities of daily living (ADLs), 
function in sport and recreation and knee- related quality 
of life, at 6 months.
Key secondary objectives are to determine, in adults 
with symptomatic knee OA:
 ► If the advice, written information and exercise 
instruction plus knee brace is superior to advice, 
written information and exercise instruction alone for 
KOOS-5 at 3 and 12 months.
 ► If the advice, written information and exercise instruc-
tion plus knee brace is superior to advice, written 
information and exercise instruction alone for the 
separate components of KOOS-5 (patient- reported 
pain, other symptoms, ADLs, function in sport and 
recreation and knee- related quality of life) at 3, 6 and 
12 months.
 ► Cost- effectiveness of the advice, written information 
and exercise instruction plus knee brace compared 
with advice, written information and exercise instruc-
tion alone.
Other secondary objectives are to determine:
 ► If the advice, written information and exercise 
instruction plus knee brace is superior to advice, 
written information and exercise instruction alone 
for: self- reported pain; instability (buckling); treat-
ment response; physical activity; social participation; 
arthritis self- efficacy.
 ► Safety of knee bracing in adults with symptomatic 
knee OA ((serious)- related adverse events (SAE)).
 ► Acceptability and experiences of the trial procedures 
and interventions to participants receiving and physi-
otherapists delivering, the trial interventions.
 ► Adherence to interventions, including exploring 
barriers and enablers of adherence to brace use in 
participants allocated to the advice, written infor-
mation and exercise instruction plus knee brace 
intervention.
A priori exploratory subgroup analyses will explore 
the effectiveness of the knee brace plus advice, written 
information and exercise instruction intervention versus 
advice, written information and exercise instruction 
alone by: (1) predominant knee compartmental involve-
ment, (2) knee buckling, (3) adherence to brace use, (4) 
anxiety/depression. We will also explore how often physi-
otherapists’ clinical judgement on appropriate brace type 
is changed by plain X- ray findings.
DESIGN
A multi- centre, primary care, randomised (1:1), parallel- 
group, superiority trial with internal pilot (see online 
supplemental datafile 1 for further details relating to the 
internal pilot and progression criteria). The trial protocol 
has been coproduced with stakeholders including 
patients.
Setting
Participants will be recruited from National Health 
Service (NHS) general practice, physiotherapy services 
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and from self- referral within the community following 
an awareness raising campaign. Interventions will be 
delivered within PROP OA knee pain clinics based in 
physiotherapy services at four NHS sites with onsite radi-
ography departments in England (Cheshire, Manchester, 
Northumbria and Staffordshire).
Eligibility criteria
The target population is adults aged ≥45 years with symp-
tomatic knee OA, moderate- to- severe pain during weight- 
bearing activity, with or without knee buckling, who have 
no current or recent knee brace use but who would be 
willing to consider using a knee brace (table 1).
Participant identification
Three methods will be used to identify potential partici-
pants, informed by our previous pragmatic trials of treat-
ments for musculoskeletal pain conditions in primary 
care43–45:
Identification of general practice consulters
Electronic records of participating general practices will 
be screened to identify adults aged 45 years and over who 
have consulted for knee pain in the last 24 months, using 
knee pain related diagnostic or symptomatic Read/Sys-
tematized Nomenclature of Medicine (SNOMED) codes. 
General practice staff will also identify potentially suit-
able participants during prospective consultations. In 
the event of slower than expected recruitment, we will 
increase the number of participating general practices 
and increase the time period for previous consultation 
with knee pain from 24 to 36 months.
Screen of physiotherapy referrals
Physiotherapy referrals will be screened to identify adults 
aged 45 years and over with knee pain potentially due to OA.
Self-referral from the community
Not all individuals with knee OA will consult healthcare 
about their knee problem. Information about the trial 
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
 ► Aged 45 years and over
 ► Residing in England
 ► Clinically significant knee pain on weight bearing (NRS ≥4)
 ► With or without knee instability (buckling)
 ► Able to have knee X- ray
 ► Able to read and write English
 ► Access to a mobile phone that can receive SMS text 
messages
 ► Able to give full informed consent
 ► Willing to participate
 ► Red flags in the history or clinical examination that may 
indicate further investigation or referral for possible serious 
underlying pathology (NICE V.5.1.1.10)
 ► Vulnerable individuals (eg, in palliative phase of care for 
cancer, unstable mental health disorders).
 ► Inflammatory/crystal arthritis (eg, rheumatoid arthritis, gout, 
psoriatic arthritis).
 ► Significant neurological disorder (eg, stroke, Parkinson’s 
disease, multiple sclerosis, dementia).
 ► Fibromyalgia.
 ► Symptoms not attributable to knee OA.
 ► Previous major surgery in the knee to be treated (partial/
total knee replacement; high tibial osteotomy, not other 
previous arthroscopic surgery).
 ► Autologous cartilage implantation in last 12 months in the 
knee to be treated
 ► On the waiting list for total hip or knee replacement within 
the next 6 months.
 ► Unwilling to wear a knee brace.
 ► Brace size unavailable for leg circumference.
 ► Knee brace contraindicated (superficial wounds where 
the knee brace would reside, psoriasis, eczema or poor 
circulation, arterial insufficiency, or severe varicosities that 
could result in skin at risk with regular brace wear, a history 
of thrombophlebitis in either leg).
 ► Significant fixed flexion deformity that prevents fitting of 
brace.
 ► Injection in the knee to be treated within the last 3 months.
 ► Recent/routine knee brace wear within the last 3 months.
 ► Nursing home resident.
 ► Unable to attend clinic.
 ► Close family member already a trial participant.
 ► Course of physiotherapy for the knee to be treated in the 
last 3 months.
NICE, National Institute for Health and Care Excellence; NRS, Numerical Rating Scale; OA, osteoarthritis.
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will be disseminated in the local communities around 
the participating sites via an awareness raising campaign. 
Interested participants will telephone the trial adminis-
trator to register their interest.
Screening
Identified individuals will be mailed a covering letter 
and Participant Information Leaflet (PIL). If interested 
in participating they will be asked to telephone the trial 
team: a trial administrator will check initial eligibility and 
answer any questions. Individuals who fulfil telephone 
eligibility criteria and are willing to participate will be 
invited to attend further face- to- face screening (Clinical 
Eligibility Assessment). At this visit activities will include:
Confirmation of eligibility assessment by a PROP OA-trained 
physiotherapist
A clinical examination will be undertaken to confirm eligi-
bility and to determine, on clinical grounds, the predom-
inant knee compartment affected (medial tibiofemoral, 
lateral tibiofemoral, patellofemoral, no clear predomi-
nant compartment).
Plain X-rays of knees (if needed)
To minimise unnecessary radiation exposure, we will 
attempt to access and read any knee X- rays taken within 
24 months where they exist. We will obtain new knee 
X- rays for eligible participants who have no knee X- rays 
within 24 months, or whose knee X- rays are unobtain-
able/unsuitable (eg, poor- quality images, lack necessary 
views). All images will be taken in the radiology depart-
ments at each site using National Health Service (NHS) 
standard protocols. The treating physiotherapist will 
assess the X- rays for the purpose of producing an overall 
judgement on the most severely affected compartment.
After 2 weeks (to allow reporting of X- rays), eligible 
participants willing to participate in the trial will attend a 
‘Treatment Visit’ where informed consent will be obtained 
(by a trial physiotherapist), baseline data collected, rando-
misation performed and trial treatments provided.
Allocation
Using Keele Clinical Trial Units (CTUs) computerised 
web- based randomisation service and random number 
generator, eligible participants recruited to the trial will 
be randomly assigned to receive either advice, written 
information and exercise instruction alone or advice, 
written information, and exercise instruction plus knee 
brace, using a 1:1 allocation ratio and random permuted 
blocks. This is a secure randomisation system with emer-
gency telephone back- up. Randomisation will be strati-
fied by physiotherapy clinic site (Cheshire, Manchester, 
Northumbria and Staffordshire), predominant compart-
mental distribution of knee OA based on combination of 
clinical assessment and X- rays, and by presence of insta-
bility (buckling). Randomisation will be executed in real 
time within the Treatment Visit by a clinic administrator. 
The randomisation code will be allocated only after the 
participant has been recruited into the trial, and after all 
baseline data are collected. The randomisation schedule 
will be password protected to ensure that allocation 
remains concealed from all staff involved in the randomi-
sation process. Thus our procedures ensure baseline data 
are collected prior to randomisation, that the allocation 
is concealed until after the participant has been recruited 
into the trial and until the moment of randomisation and 
that the person assigning participants to intervention arm 
(clinic administrator) has no involvement in the eligibility 
screen, consent or treatment processes.
Blinding
Within this trial it is impossible to blind participants or 
physiotherapists to treatment allocation. However, a trial 
administrator will oversee collection of baseline ques-
tionnaire data ahead of treatment allocation and a trial 
administrator will remain blind to treatment allocation 
to enable them to conduct Minimum Data Collection 
(MDC) over the telephone free of allocation bias. The 
trial statistician who will be performing analysis of the 
data collected will also be blind to treatment allocation.
Interventions
Comparator: advice, written information and exercise instruction
A single, face- to- face, 20 min consultation with a physio-
therapist that, in line with NICE core treatment recom-
mendations for OA,10 will include: verbal and written 
education regarding pathogenesis and prognosis of 
knee OA and the benefits of exercise, increasing phys-
ical activity and weight loss; simple self- help advice on 
pain management, including home- use of heat/cold, 
pacing of activities and simple analgesia (we will use the 
Osteoarthritis Guidebook (https://www. keele. ac. uk/ 
media/ keeleuniversity/ ri/ primarycare/ pdfs/ OA_ Guide-
book. pdf) with minor trial- specific changes adapted 
by Public and Patient Involvement and Engagement 
(PPIE)); and advice to complete a home- based lower 
limb exercise programme focusing on muscle strength-
ening, knee range of movement and proprioception (see 
online supplemental datafile 2). This reflects ‘best care’ 
routinely available in primary care where knee OA is typi-
cally managed. The content of the advice and exercises 
was informed by our previous knee OA trials testing phys-
iotherapist led OA care.44 46
Intervention: advice, written information and exercise instruction 
plus knee brace with adherence enhancing component
An initial 1- hour face- to- face treatment session with a 
physiotherapist, a 30 min face- to- face follow- up appoint-
ment with the physiotherapist 2 weeks later, and motiva-
tional prompts to enhance brace adherence sent via SMS 
text message over 6 months.
Initial treatment session
Participants will receive advice, written information and 
exercise instruction as described above, plus knee brace 
and adherence enhancing components.
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Knee brace
In addition to advice, written information and exercise 
instruction, participants will be given either a patellofem-
oral, tibiofemoral unloading, or neutral stabilising knee 
brace according to whether their pattern of knee OA 
was predominantly patellofemoral OA, tibiofemoral OA 
(medial/lateral) or generalised knee OA. This will be 
based on clinical assessment and X- ray findings, but also 
taking into account current and desired level of physical 
activity, ability to don/doff brace, willingness to wear the 
brace type, and immediate symptom response when the 
brace is tried on and tested in clinic. Braces will be fitted to 
ensure maximum comfort (eg, hinges contoured, straps 
adjusted and cut to match participants’ body shape and 
size). Dose of brace use will be individually tailored. Partic-
ipants will be advised to wear the brace on painful weight- 
bearing activity, with a starting minimum usage of 1 hour 
on ≥2 days/week, gradually increased based on tolerance 
to wearing the brace on all painful weight- bearing activi-
ties up to a maximum of 8–12 hours/day. Individuals will 
be advised to wear the brace for 6 months and continue 
to wear it beyond this time if they find it beneficial. Verbal 
and written information will be provided on brace appli-
cation and care, including cleaning instructions and what 
to do in instances of slippage, discomfort or skin irrita-
tion. Supporting patient material (eg, written informa-
tion, short video clips) on brace application produced by 
the brace manufacturers will be available.
The braces selected for use in this trial are from the 
two most- referenced manufacturers in the medical liter-
ature (Össur and Donjoy)47 and the manufacturer of 
the patellofemoral brace (Bioskin) previously demon-
strated to be clinically effective in a similar popula-
tion as intended with the current trial.40 The braces, by 
type, are: patellofemoral—Bioskin Q Brace; tibiofem-
oral unloading—Össur Unloader One (first choice), 
Donjoy OA Nano (second choice); neutral stabilising—
Össur Formfit Knee Hinged. These have been selected 
to provide an appropriate brace within each brace type, 
based on previous trial experience and evidence, PPIE 
feedback and expert opinion (including Clinical Advisory 
Group (CAG) members’ views).
Brace adherence enhancing component
Brief motivational interviewing (MI) techniques will 
be used to build participants’ intrinsic motivation and 
resolve ambivalence about adhering to brace use.48 The 
techniques will be based on brief strategies to enhance 
motivation to change,48 including both communication 
strategies and motivational techniques. Communication 
strategies include: (1) open- ended questions that invite 
patients to provide their thoughts about brace adherence 
in a non- judgemental atmosphere, (2) use of affirma-
tions or statements that creates rapport and recognises 
participants’ strengths and small steps towards improved 
adherence; (3) reflective listening to convey provider 
understanding, provide new perspectives on their situa-
tion and help providers deal with resistance and (4) use of 
summaries to help resolve ambivalence and highlight the 
patient’s self- motivational statements. Motivational tech-
niques include (1) helping the patient weigh the costs 
and benefits of adherence to brace use, (2) providing 
education and feedback on adherence using the ‘elicit- 
provide- elicit’ process, (3) exploring barriers and facili-
tators of motivation to adhere and confidence to adhere, 
and (4) discuss how adherence can enhance, rather than 
detract from, things they most highly value (values clari-
fication). Participants will be provided with a diary which 
they can use to record whether they have worn the brace, 
for how long, if not what were the barriers to wearing 
the brace, and what are the possible solutions to those 
barriers.
Follow-up treatment session
During the follow- up consultation the physiotherapist 
will check response to, and fit of the brace. For partici-
pants who report tolerating it well and finding it helpful, 
brace use will be increased for longer durations of painful 
weight bearing activity. If participants are experiencing 
discomfort or not finding it helpful, brace fit and dose 
may be reduced. In extreme cases, if the brace is not toler-
ated, it may be changed. Adherence to brace use will be 
reviewed and addressed using brief MI techniques and 
based on information provided within the brace diary.
Motivational prompts to enhance brace adherence
Motivational prompts to encourage brace adherence will 
be sent to individuals receiving advice, written informa-
tion and exercise instruction plus knee brace interven-
tion via Short Message Service (SMS) text message. The 
content of these texts will be tailored to the level of brace 
use reported by the participant (low: wearing knee brace 
on less than 2 days per week; mid: wearing knee brace on 
2–4 days per week for 1 or more hours per day or wearing 
knee brace on 5–7 days per week for 1–3 hours per day: 
high: wearing knee brace on 5–7 days per week for 4 or 
more hours per day). For example, patients who have low 
use will receive texts that target their ambivalence about 
wearing the brace; those with moderate levels of use will 
receive texts about problem solving and barriers along 
with some motivational strategies and those with the 
highest level of use will receive congratulatory messages 
and messages regarding potential benefits they may have 
incurred. Motivational prompts will be sent weekly for the 
first 4 weeks, fortnightly for the next 8 weeks, and then 
monthly until the intervention period ends at 6 months.
Cointerventions
All participants will be advised that they can continue 
to access usual healthcare, including medications and 
consultations with other health professionals. Participants 
allocated to the comparator arm will be asked not to wear 
a knee brace for the 6- month period following rando-
misation. Details of cointerventions will be recorded in 
follow- up questionnaires.
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Study training
Physiotherapists delivering trial interventions will be repre-
sentative of the range of physiotherapists that patients 
would see beyond the trial in the UK NHS setting. Partic-
ipating physiotherapists will deliver both interventions 
and will receive a 3- day PROP OA training programme 
prior to the trial starting, regular reminders regarding 
the content of treatment sessions for the first 3 months, 
and refresher training at 6 months and 1 year. Training 
will cover all trial aspects including: clinical assessment; 
reading and interpretation of plain knee X- rays to judge 
compartmental involvement and inform brace allocation; 
provision of trial interventions, including dovetailing 
the provision of knee braces with brief MI techniques 
to facilitate brace adherence and Good Clinical Practice 
(GCP) and trial procedures. To promote protocol fidelity, 
the training programme will be delivered using interac-
tive group discussion, problem solving, case examples 
and role play. In addition, physiotherapists will receive 
a PROP OA manual to following when delivering both 
interventions. Physiotherapists will record intervention 
provision using case report forms (CRFs), which will be 
monitored over the course of the trial and used to assess 
ongoing treatment fidelity.
Outcomes
The end points are defined as: primary end point at 6 
months for clinical effectiveness and at 12 months for 
cost- effectiveness analysis, and withdrawal for any reason. 
A schedule of enrolment, interventions and assessments 
is provided in table 2.
The primary outcome is patient- reported composite 
knee score of patient reported pain, other symptoms, 
ADLs, function in sport and recreation and knee- related 
quality of life (KOOS-5).49
Secondary endpoints/outcomes
Secondary outcomes include patient reported pain, other 
symptoms, ADLs, function in sport/recreation and knee- 
related quality of life (KOOS subscales),49 pain (pain on 
weight- bearing activity (Numerical Rating Scale)), inter-
mittent and constant pain (ICOAP)50; instability (buck-
ling)51; Osteoarthritis Research Society International 
responder criteria52 53; physical activity (International 
Physical Activity Questionnaire- Elderly54; social partici-
pation (PROMIS)55 56; arthritis self- efficacy57; treatment 
acceptability58; (SAE) . KOOS Pain items contain those 
needed to score Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) Pain, KOOS ADLs 
score is the same as WOMAC Physical Function score and 
KOOS-4 can be easily computed: all of which permits 
wider comparison of findings and facilitates future indi-
vidual participant data (IPD) meta- analysis (see table 2).
Cost-effectiveness
Outcomes include the EQ- 5D- 5L questionnaire59 and self- 
reported knee OA- related resource use related to both 
primary and secondary care consultations, inpatient stays 
and treatment including surgery. Data will be collected 
within the trial to determine the cost of the interventions 
(physiotherapist time, cost of braces). Unit costs from 
standard UK sources will be sought for all healthcare 
resource use items. Data on broader costs will also be 
collected, related to both out of pocket costs (eg, over- 
the- counter medications), private healthcare and time off 
work to calculate productivity losses.
Time to and receipt of knee surgery (knee arthroscopy and knee 
joint replacement)
All participants will be invited to consent to linkage of 
their trial data to the Hospital Episode Statistics and 
National Joint Registry and medical record review to 
enable future evaluation of receipt of knee arthroscopy 
and knee joint replacement.
Adherence
Adherence to interventions will be measured via self- 
report in follow- up questionnaires (using similar 
questions to those we have used in previous trials of non- 
pharmacological care for OA).44 In those randomised 
to advice, written information and exercise instruction 
plus knee brace, SMS text messages will also seek data 
on number of days per week and hours per day of brace 
usage, sent on a tapering schedule over the first 6 months 
of follow- up, with a text message also at 12 months. We 
will seek to include an objective measure of adherence to 
brace use, with participants blinded to this.
Adverse events
The occurrence of adverse events considered to be 
related to the trial interventions for each intervention 
will be monitored and assessed using CRFs, contact with 
the trial team, physiotherapist report and follow- up ques-
tionnaires. Expected adverse events from knee braces for 
knee OA include: swelling, blisters and skin irritation. An 
expected adverse event from unaccustomed exercise and 
physical activity is temporary, mild muscle soreness. An 
SAE is an untoward event that: (1) results in death; (2) is 
life threatening; (3) requires hospitalisation or prolonga-
tion of existing hospitalisation; (4) results in persistent or 
significant disability/incapacity; (5) consists of a congen-
ital anomaly/birth defect or (6) is otherwise considered 
medically significant. Where an SAE is considered to be 
potentially related to trial procedures, reporting proce-
dures will be followed that are in accordance with GCP 
guidance. All SAEs either confirmed or suspected to be 
related to the trial procedures will be considered by the 
external monitoring committees.
Data collection
All trial participants will be asked to complete a paper 
questionnaire at, or just prior to, the baseline clinic 
appointment and a posted questionnaire after 3, 6 and 
12 months postrandomisation (see table 2 for a summary 
of questionnaire content). Standard Keele CTU proce-
dures will be followed to maximise follow- up, including 
postcard and questionnaire reminders. In addition, a £10 
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Table 2 Schedule of enrolment, interventions and assessments
Time point
Enrolment Random allocation Post- randomisation
−8 to −0 weeks 0 2 weeks 3 months 6 months 12 months
Enrolment
Telephone eligibility assessment X
Informed consent to assessment X
Clinical eligibility assessment X
Knee X- ray acquisition/reporting X
Knee X- ray assessment X





Advice, written information and 
exercise instruction
X









Frequent knee symptoms in last 
month
X
KOOS-5* X X X X
KOOS Activities of Daily Living† X X X X
KOOS Pain† X X X X
KOOS Symptoms† X X X X
KOOS Sports/Recreation† X X X X
KOOS Quality of Life† X X X X
KOOS-4 X X X X
Knee pain on weight- bearing 
activity
(0–100 NRS)†
X X X X
Intermittent and Constant Pain 
(ICOAP)
X X X X
Knee buckling‡ X X X X
Physical activity (IPAQ- E) X X X X
Arthritis self- efficacy X X X X
HADS: Anxiety X
HADS: Depression X
PROMIS Social participation X X X X
Adverse events X X X X
Adherence§ X X X X
Patient global rating of change¶ X X X




EuroQol EQ- 5D- 5L X X X
Continued
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gift voucher will be sent to participants along with their 3, 
6 and 12 months follow- up questionnaires.60 At 6 months 
follow- up, the primary end point, non- responders will be 
approached for MDC 2 weeks after the reminder ques-
tionnaire is mailed. MDC is a shorter version of the self- 
report outcome questionnaire and will be used to collect 
the primary and limited secondary outcome measures 
(KOOS-5), global change scores and EQ- 5D- 5L, along 
with date of birth and gender to ensure the data are 
provided by the intended participant. If no response 
to the MDC questionnaire, we will attempt to collect 
minimum data over the telephone by a trial adminis-
trator. Data on self- reported adherence to brace use (in 
the advice, written information and exercise instruction 
plus knee brace intervention group) will be collected by 
two- way SMS text messages at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 
24 and 52 weeks. A schematic diagram of the participant 
flow chart is provided in figure 1.
Bracing trials show standardised effect sizes (ES) for 
short- term improvements in knee pain and function of 
0.33–0.56 and 0.22–0.48, respectively, for tibiofemoral 
unloading braces24 and 0.61 and 0.39, respectively, for soft 
neoprene sleeve braces.25 Our trial is powered to detect 
a between- group ES of 0.35 (small- to- medium effect) 
in the primary outcome at 6 months with two- sided 5% 
significance and 90% power, which, assuming an SD of 
23 as estimated from previous trial data,44 equates to a 
minimum clinically important difference (MCID) of 
8- points on the KOOS-5; an MCID value that aligns with 
published evidence for the tool.61 We will randomise 434 
patients, recruited over a period of 24 months, to allow 
for 20% lost to follow- up at 6 months,44 46 62 (target n at 6 
months=346; 173/arm). We have not inflated our sample 
size for therapist effects as each physiotherapist will be 
trained to deliver both interventions, however, the thera-
pist will be included as a covariate in a sensitivity analysis 
of the treatment models to increase model power.63
Statistical methods
A separate a priori data analysis plan will be written to 
describe all trial analysis. Consequently, only a brief 
outline is outlined below.
A Consolidated Standards of Reporting Trials flow 
diagram will describe the flow of participants through 
the study and will include reasons for trial withdrawal if 
given. Descriptive statistics will be used to describe the 
key baseline characteristics of participants at each stage of 
recruitment and follow- up, and by intervention arm. The 
primary outcome analysis will be on an intention- to- treat 
Time point
Enrolment Random allocation Post- randomisation
−8 to −0 weeks 0 2 weeks 3 months 6 months 12 months
Healthcare resource use (NHS/
private)
X X X X
Out- of- pocket expenses X X X
Time off work X X X
*Primary outcome.
†Key secondary outcomes.
‡Single item used for stratified randomisation, multiple items used for outcome evaluation.
§Obtained in part through: two- way SMS text messages at weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 52; self- report via questionnaire at 3, 6 
and 12 months.
¶Measure used only to classify OMERACT- OARSI responder.
**Close- out at 12 months for analysis of clinical effectiveness.
HADS, Hospital Anxiety and Depression Scale; ICOAP, Intermittent & Constant Osteoarthritis Pain; IPAQ- E, International Physical Activity 
Questionnaire- Elderly; KOOS, Knee Osteoarthritis Outcomes Score; NHS, National Health Service; NRS, Numerical Rating Scale; OARSI- 
OMERACT, Osteoarthritis Research Society International; PROMIS, Patient- Reported Outcomes Measurement Information System.
Table 2 Continued
Figure 1 Participant flow and timeline. CTU, Clinical Trial 
Unit; GP, general practitioner; OA, osteoarthritis.
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basis and will compare the primary outcome (KOOS-5) 
at the primary endpoint (6 month follow- up) for advice, 
written information, and exercise instruction plus knee 
bracing versus advice, written information and exercise 
instruction alone. Secondary analysis will include the anal-
ysis of the primary outcome at 3 and 12 months (ie, the 
secondary endpoints) and the secondary clinical effective-
ness outcomes at 3, 6 and 12 months. Analysis of covari-
ance will be used to model outcomes that are continuous 
and logistic regression for those that are dichotomous. 
All models will be reported after adjustment for a priori 
analysis covariates (as defined in the a priori analysis 
plan) and after imputation of missing data. Treatment 
effect estimates will be presented as mean differences or 
ORs (as appropriate) with 95% CIs. Longitudinal mixed- 
effects models will also be used to evaluate the treatment 
effect at each single time point and over time to check 
that results are consistent with those derived from the 
primary analysis.
Exploratory subgroup analyses will be performed (if 
numbers in each subgroup are sufficient for these analyses 
to be feasible) based on the presence of knee instability 
(buckling), predominant knee compartment involved, 
level of adherence and anxiety/depression. Participants 
will also be included in a per- protocol analysis if they meet 
prespecified inclusion criteria, defined fully in the a priori 
analysis plan. Cross- tabulation and the kappa statistic will 
be used to test how accurate brace allocation would have 
been if based on clinical judgement alone, rather than 
on clinical assessment findings and X- ray assessment 
combined. Treatment acceptability will be described 
using numbers and percentages. Any adverse events and 
protocol violations will be reported throughout the trial 
by intervention arm. No interim analysis will be under-
taken during the trial to assess the clinical effectiveness 
of advice, written information and exercise instruction 
plus knee bracing over advice, written information and 
exercise instruction alone, however, an internal pilot trial 
phase will be conducted with prespecified progression 
criteria (online supplemental datafile 1).
Economic evaluation
Within trial economic evaluation
An economic evaluation will be undertaken alongside the 
trial to estimate the cost- effectiveness of advice, written 
information and exercise instruction plus knee bracing 
versus advice, written information and exercise instruction 
alone in the management of knee OA. An incremental 
cost–utility analysis will estimate cost per quality- adjusted 
life year (QALY) over 12 months follow- up. QALYs will be 
calculated from responses to the EQ- 5D- 5L questionnaire 
using the ‘area under the curve’ approach. The cross- 
walk value set to obtain utility scores, in line with current 
NICE recommendations64 and the more recent English 
value set will be used in a sensitivity analysis. The base- 
case analysis will be from a healthcare perspective, with 
an additional analysis from a societal perspective taking 
into account out- of- pocket costs and work productivity 
losses. Mean resource use (for each category of health-
care usage) and mean total costs will be calculated for all 
trial participants. Analysis of productivity losses will use 
the human capital approach, and the self- reported days 
of absence will be multiplied by the respondent- specific 
wage rate. Multiple imputation will be used to impute all 
missing values for the EQ- 5D and total cost estimates for 
missing data at follow- up. Incremental cost–utility anal-
ysis will be undertaken to estimate the incremental cost 
per QALY gained, adjusting for baseline covariates. The 
robustness of the results will be explored using sensitivity 
analysis. Cost- effectiveness acceptability curves will also be 
produced to reflect the probability the intervention will 
be cost- effective at different cost per QALY willingness to 
pay thresholds.
Model-based health economic analysis
Decision modelling, using a Markov model, will also be 
undertaken to extend beyond 12 months follow- up, to 
extrapolate costs and QALYs over a lifetime time horizon. 
The cost–utility analysis will be from an NHS perspective, 
with discounting of costs and outcomes at 3.5%. In addi-
tion to trial data, the model will be populated with data 
from existing literature on the natural history of symp-
tomatic knee OA, risks associated with surgery and quality 
of life, and national data on all- cause mortality. The 
model will be subject to deterministic sensitivity analysis 
by changing individual parameter values and changing 
model assumptions, and probabilistic sensitivity analysis 
to simultaneously incorporate all parameter uncertainty. 
Cost- effectiveness planes and cost- effectiveness accept-
ability curves will be presented to show the probability 
that advice, written information and exercise instruction 
plus knee bracing is cost- effective at different cost/QALY 
thresholds.
Nested qualitative studies
In addition to qualitative interviews undertaken in the 
internal pilot phase (online supplemental datafile 1), a 
theoretically informed qualitative study will be completed 
within the main trial, which builds on our previous work 
exploring acceptability of, and adherence to, physio-
therapy- led interventions for individuals with knee OA, 
and barriers and facilitators to non- pharmacological 
interventions (exercise and physical activity) in this 
population.65–67
To help explain the results of the trial in terms of the 
comparable clinical effectiveness of interventions, a 
qualitative study will investigate contextual factors, and 
barriers and enablers to brace use in individuals with knee 
OA. Drawing on normalisation process theory (NPT)68 69 
and the theoretical domains framework (TDF),70 we will 
investigate patient and physiotherapy perspectives and 
will undertake:
Semistructured interviews (face to face or telephone) 
with ≤40 participants postintervention (at 6 months 
follow- up) (n≤20 from each treatment arm). Partici-
pants will be purposefully sampled from both treatment 
 on A









pen: first published as 10.1136/bm





10 Holden MA, et al. BMJ Open 2021;11:e048196. doi:10.1136/bmjopen-2020-048196
Open access 
arms (using data from trial questionnaires and SMS text 
messages) to ensure a diverse range of characteristics 
including age, sex, knee compartmental involvement, 
baseline pain severity, presence/absence of buckling, 
perceived overall improvement and level of adherence. 
The interview topic guide will explore participants’ expe-
riences of trial interventions, adherence to interventions 
(including barriers and enablers to brace adherence in 
the advice, written information and exercise instruction 
plus knee brace intervention arm), and impact of inter-
ventions on participants’ symptoms, functioning and 
quality of life. Perceived harms and adverse events from 
interventions will also be explored. Data collection and 
analysis will be carried out iteratively so that emerging 
themes can be effectively explored in subsequent inter-
views.71 Sampling will continue until no new themes 
emerge.
Semistructured interviews will be conducted with phys-
iotherapists who delivered trial interventions (n≤16) after 
they have treated their final trial participant. Interviews 
will provide insight into experiences of implementing, 
embedding, accepting and integrating both advice, 
written information and exercise instruction and the 
addition of knee bracing into NHS physiotherapy services. 
The topic guide will cover the appropriateness of the trial 
training programme, physiotherapists’ views of their roles 
in the trial in terms of delivering usual practice (advice/
education/exercise prescription) but in only one treat-
ment session, and in the advice, written information and 
exercise instruction plus knee bracing arm, the extra 
activity including using a standardised clinical assessment 
to identify compartment of knee affected by OA, assess-
ment of X- rays, prescribing a brace and supporting the 
patient to use it, changing it where necessary, and using 
brief MI techniques specifically to facilitate adherence to 
brace use.
All interviews will be audiorecorded, transcribed 
verbatim, checked and anonymised for analyses. Initially, 
each interview transcript will be read and reread to iden-
tify and code discrete parts of the data that represent a 
particular concept. As analysis continues, using principles 
of constant comparison,71 data will be closely examined 
for similarities and differences, and groups of words or 
phrases representing the same concept will be grouped 
into themes. Emerging codes and themes will be discussed 
and agreed with members of the study team (including 
PPIE team members) on an ongoing basis and applied to 
the dataset with ongoing refinement as needed. Inductive 
analysis (described above) will precede deductive analysis 
and mapping of themes to TDF or NPT constructs.68 70 
This layered approach enables a rich interpretative anal-
ysis to be completed as emergent issues are identified 
ahead of making sense of data according to theoretical 
constructs.68 72 Data will be used to inform an implemen-
tation strategy in conjunction with Keele’s Impact Accel-
erator Unit.
DATA MANAGEMENT
Self- report questionnaires, SMS text messages and CRFs 
will form the basis of data collection. All data collected 
during the course of the trial will be handled and stored 
in line with Keele University’s Data Security procedures 
and Standard Operating Procedures (SOPs), which are 
in accordance with the Data Protection Act 2018, other 
relevant regulations and GCP guidelines. If a participant 
withdraws consent from trial intervention and/or further 
collection of data, their data will remain on file and 
included in the final analysis. At the end of the trial, data 
will be securely archived in line with the Sponsor’s proce-
dures for a minimum of 5 years. Data held by Keele CTU 
will be archived in the designated Keele CTU archive 
facility and site data and documents will be archived at 
the participating sites. Following authorisation from the 
Sponsor, arrangements for confidential destruction will 
then be made.
TRIAL ORGANISATION
The trial steering committee (TSC) met prior to ethics 
application in order to agree the final protocol, and will 
continue to meet at agreed time intervals over the course 
of the trial. An independent data monitoring committee 
approved the protocol and reviews the safety of the trial. 
Detailed reports focusing on interim safety, recruitment 
and retention are prepared by Keele CTU at approxi-
mately 6 monthly intervals. All data collection, database 
design, data input and cleaning, as well as trial oversight 
procedures, are in line with the Keele University SOPs 
and the conditions of the grant. Data will be centrally 
monitored for quality and completeness by Keele CTU.
PUBLIC AND PATIENT INVOLVEMENT
Two patient representatives are members of the trial 
team and helped write the grant application and actively 
contributed to revising the trial protocol following CAG 
and Panel feedback. A 3- hour workshop was convened 
with five patient representatives with knee OA to discuss 
recruitment, participant flow, interventions (including 
trying on/ discussing patellofemoral, tibiofemoral 
unloading and neutral stabilising knee braces), outcome 
measures and dissemination. Comments about the trial 
were obtained from the general public via the interac-
tive VoiceNorth discussion forum and specific feedback 
from nine VoiceNorth members (http://www. voicenorth. 
org/). As a result, changes were made to the recruitment 
strategy, outcome measures and the collection of infor-
mation on reasons for non- adherence.
To further refine the design of the trial, a second PPIE 
workshop was convened in the pretrial phase to finalise 
the adherence- enhancing SMS intervention (eg, content 
of text messages). To help inform the development of the 
PROP OA trial protocol, we also formed, and convened 
two workshops with, a CAG consisting of multidisci-
plinary clinicians involved in the PROP OA. Our PPIE 
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coapplicants actively participated in these workshops 
which shaped the eligibility criteria, intervention content 
and processes of brace selection.
Internal pilot phase findings and potential changes 
needed to the trial will be discussed with lay members. 
To ensure ongoing oversight PPIE study members will 
attend TMG meetings, and assist in the interpretation of 
qualitative findings. Two independent lay members will 
also sit on the TSC. Finally, PPIE study members will play 
an important role in developing easily understandable 
key messages about trial findings for our dissemination 
strategy. With the CAG, PPIE members will inform the 
implementation strategy with the Impact Accelerator 
Unit. We have an established track record in publishing 
our PPIE related work.43–78 All PPIE activity will follow our 
written framework for PPIE involvement that is based on 
INVOLVE guidelines,79 and will be supported by our User 
Support Worker.
ETHICS AND DISSEMINATION
Ethical and regulatory considerations
This clinical trial has been designed, and will be run, 
in accordance with the principles of GCP. The trial 
involves the investigation of interventions in practice. 
All braces used in the trial are CE marked mass- product 
(not custom- made) medical devices being used for their 
intended purpose.
All patients will receive advice, written information and 
exercise instruction that aligns with best evidence recom-
mendations from NICE.10 All interventions are deemed 
safe, with few and minor expected adverse events (e skin 
irritation from knee braces, muscle soreness from exer-
cise). Participants in both intervention arms will be able to 
consult for healthcare in addition to the care they receive 
within the PROP OA trial, and this will be recorded and 
analysed. Participation in the trial may involve exposure 
to ionising radiation in the form of plain radiography to 
obtain knee X- rays at baseline. Imaging procedures will 
be compliant with the Ionising Radiation (Medical Expo-
sure) Regulations 2000 and the amendments in 2006 and 
2011.
Research ethics approval
This project received a favourable ethical opinion from 
North West Preston Research Ethics Committee (IRAS 
Reference: 247370; REC Reference: 19/NW/0183) and 
approval from the Health Research Authority (HRA) and 
Health and Care Research in Wales (HCRW) on (19 June 
2019). The imaging protocol was reviewed prior to REC 
submission by an independent Medical Physics Expert 
and Clinical Radiation Expert.
Protocol amendments
This is an edited version of full current protocol V.2.2 (4 
March 2020). The full version of the protocol is available 
at https:// fundingawards. nihr. ac. uk/ award/ 16/ 160/ 03.
DISSEMINATION POLICY
Our main findings on the clinical and cost- effectiveness 
of adding knee bracing to advice, written information 
and exercise instruction will have important implications 
for patients and the NHS. To ensure that the outputs 
from the research inform clinical practice, our dissemi-
nation strategy will use multiple modes of communica-
tion to reach five key audiences for this research: patients 
with knee pain/OA and the wider public; healthcare 
professionals; Clinical Commissioning Groups and 
commissioning organisations; external statutory bodies, 
patient groups and charities; academia. Keele’s Impact 
Accelerator Unit will work close with the research team 
throughout the study to shape an implementation strategy 
and identify key innovations for adoption.
AVAILABILITY OF DATA AND MATERIALS
Keele University is a member of the UK Reproducibility 
Network and committed to the principles of the UK 
Concordat on Open Research Data. The School of Medi-
cine and Keele CTU have a long- standing commitment to 
sharing data from our studies to improve research repro-
ducibility and to maximise benefits for patients, the wider 
public and the health and care system.
Metadata, including study protocol, statistical analysis 
plan, data dictionaries and key study documents (PIL, 
blank/coded CRFs, consent form), will be deposited on 
a publicly accessible repository. Deidentified IPD that 
underlie the results from this trial will be securely stored 
on servers approved by a government- backed cyber secu-
rity scheme and made available to bona- fide researchers 
on reasonable request via our controlled access proce-
dures. Unless there are exceptional circumstances, data 
will be available on publication of main study findings 
or within 18 months of study completion (whichever is 
earlier) and with no end date. Data requests and enquiries 
should be directed to  medicine. datasharing@ keele. ac. uk. 
We encourage collaboration with those who collected the 
data, to recognise and credit their contributions.
The data generated from this trial will remain the 
responsibility of the Sponsor. Release of data will be 
subject to a data use agreement between the sponsor and 
the third party requesting the data. Deidentified IPD will 
be encrypted on transfer.
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SUPPLEMENTARY DATAFILE 1. INTERNAL PILOT  
An internal pilot will be completed to enable us to check our assumptions about the sample size and to 
test key trial processes and logistical issues including recruitment, intervention fidelity, adherence to 
brace use, follow-up and retention, and outcome measurement. 
Objectives  
Specific objectives of the internal pilot are to: 
1) Check the numbers of eligible patients and rate of recruitment overall per month, per site per 
month, and per recruitment method (identification of General Practice consulters, screen of 
physiotherapy referrals, self-referral in the community following awareness raising)  
2) Explore intervention fidelity and participant adherence to brace use 
3) Check the trial retention rate 
 
Methods 
The internal pilot will last for 9 months, commencing from the start of recruitment (month 7 of the study 
timeline). All 4 sites will be included within the internal pilot, and the data collection methods used will be as 
per those of the full trial (as described above, and with an objective measure of brace adherence if deemed 
feasible within the pre-trial phase).  
 
Data collection  
Data from the following sources may be used within the internal pilot phase: telephone eligibility 
screening case report form; baseline, 3 month follow-up questionnaires (where available); text 
messaging (brace adherence data - advice, written information, and exercise instruction plus knee brace 
only); physiotherapist case report forms; recruitment database; follow-up database; adverse event log; 
preliminary qualitative interviews with participants and physiotherapists.     
 
Internal pilot qualitative study 
Based on best practice guidance,s1 the aims of the qualitative study within the internal pilot are to 
investigate: a) the acceptability of trial procedures and interventions; b) adherence to interventions 
among participants (including barriers and enablers to brace use in individuals in the advice, written 
information, and exercise instruction plus knee brace intervention arm); and c) barriers and enablers to 
successful delivery of interventions among trial physiotherapists. We will draw on Normalisation 
Process Theory (NPT)s2 to investigate the work required to deliver and adhere to bracing in the trial, 
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and to understand treatment burden.s3 We will draw on the Theoretical Domains Framework (TDF)s4 to 
understand behavioural determinants of participant adherence to, and physiotherapist delivery of, 
interventions. We will undertake: 
● Semi-structured one-to-one interviews with up to 20 trial participants (n≤10 in each 
intervention arm) at 3-months follow-up 
● Semi-structured one-to-one telephone interviews with physiotherapists who have delivered trial 
interventions within the internal pilot phase (n=up to 10).  
The findings will be used to inform the decision to progress to the main trial, identify necessary 
changes to the trial processes or interventions for the main trial, and to inform on-going physiotherapy 
training and monitoring within the main trial. 
Outcomes 
Outcomes of interest for the internal pilot include: 
1. Numbers of adults over 45 years with knee pain identified (per site; per recruitment method 
(including each awareness raising method employed); overall). 
2. Number of individuals screened, number and reasons for ineligibility/exclusion/declining 
participation at telephone and clinical screening stage, and consent/randomisation rates (per site; 
per recruitment method; overall). 
3. Retention and follow-up rates at 3 months (per site; overall). 
4. Intervention fidelity measured by number of participants who have received the interventions per 
protocol, and reasons for any protocol non-adherence (including number of treatment sessions 
provided, content of treatment sessions, crossover, and off-protocol intervention (including co-
interventions sought from participants)) (per site; overall).  
5. Brace adherence in those randomised to receive advice, written information, and exercise 
instruction plus knee brace, measured by self-report via SMS.    
6. Relative distribution of most severely affected compartment (both arms) and brace type provided 
(advice, written information, and exercise instruction plus knee brace intervention arm only). 
7. Patient and physiotherapist perceptions of acceptability of trial procedures and interventions. 
8. Barriers and enablers to interventions among participants. 
9. Barriers and enablers to successful delivery of interventions among trial physiotherapists. 
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Sample size 
We anticipate that approximately 32 participants in the advice, written information, and exercise 
instruction plus knee brace intervention arm will have 3 month data in the internal pilot, hence we can 
estimate the proportion of patients adhering to braces with at least 95% confidence and a 20% margin 
of error, assuming adherence and fidelity rate of 50% as a worst case scenario for desired precision.s5 
As other important estimates of recruitment and follow-up will be derived from participants with data 
in both intervention arms, their estimated precision in the internal pilot study will be greater than that 
for adherence and intervention fidelity (which is estimated from the advice, written information, and 
exercise instruction plus knee brace intervention arm only). 
 
Progression criteria 
A success criteria traffic-light system relating to the internal pilot trial objectives will be used to inform 
whether we ‘stop’ ‘proceed’ or ‘proceed but with protocol amendments’ to the full trial.s5 These 
criteria are shown in the table below and will be finalised with the Trial Steering Committee (TSC) and 
funder in the pre-trial phase.s5 We recognise the arbitrary nature of these cut-offs, however having 
them in place will allow us to identify any issues that are addressable in going forward to a main trial.s5 
Qualitative findings will also be available to the TMG, TSC and funder at the time of decision making 
regarding progression of the pilot trial. These will be used to help understand the findings of the 
internal pilot and will be used to help make the final decision as to whether we should stop, proceed, or 
proceed but with protocol amendments to the full trial. 
 
Progression criteria for internal pilot 
 
 Proceed to main trial Proceed to main trial with 
protocol amendments 
Do not proceed to main trial 
Recruitment  
In months 7-9 of 
recruitment: 
Site has recruited over 4 
participants per month; 
recruited 19 participants per 
month overall 
Site has recruited 3-4 
participants per month; 
recruited 12-18 participants per 
month overall 
Site has recruited fewer than 3 
participants per month; 
recruited fewer than 12 
participants per month overall 
Intervention 
fidelity  
Interventions delivered per 
protocol for at least 75% of 
participants (per site; 
overall)   
Interventions delivered per 
protocol for 45-75% of 
participants (per site; overall)   
Interventions delivered per 
protocol for fewer than 45% of 
participants (per site; overall)   
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knee brace arm 
only) 
At least 75% of participants 
reporting minimal level of 
brace adherence at 3 months* 
(per site; overall) 
Between 45-74% of 
participants reporting minimal 
level of brace adherence at 3 
months* (per site; overall) 
Fewer than 45% of participants 
reporting minimal level of 
brace adherence at 3 months* 
(per site; overall)  
Retention and 
follow-up at 3 
months  
At least 75% retention and 
follow-up at 3 months (per 
site; overall) 
Between 50-74% retention and 
follow-up at 3 months (per site; 
overall) 
Fewer than 50% retention and 
follow-up at 3 months (per site; 
overall) 
*Minimal level of brace adherence: wearing the brace for 1 hour on two or more days per week 
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The following exercise programme is designed to increase the movement in your knee joint, 
strengthen the muscles that support your knee, and improve your balance. Always start any exercise 
programme very gently. A slight increase in pain is not uncommon during the first 1-2 weeks, since it 
is normal to feel a generalised ache or fatigue in the muscles you have been exercising. If you 
experience severe or persistent pain beyond this time point, stop the exercise programme and seek 
advice from your GP. 
 
How often should I exercise? 
Try to do the exercise programme 2 or 3 times per week, waiting for at least 48 hours between 
sessions. 
 
Try to complete 8-12 repetitions of each exercise. Repeat the same exercise 1-3 times. Rest for a few 
minutes before you move onto the next exercise. Build up the number of exercise repetitions you do, 
and the number of times you complete each exercise gradually.  
 
If you feel a sharp pain whilst you are doing any of the exercises, then this might mean that you are not 
doing them correctly. Stop and rest until the pain has eased. Read the instructions again, and try again. 
 
How long should I continue for?  
It would be beneficial for you and your knee if you are able to continue these exercises 









1. Sit on a chair with your feet on the floor. 
Bend your knee as much as possible and then straighten it. 
2. Sit on a chair.  
Pull your toes up, tighten your thigh muscle and straighten your knee. Hold for 
approximately 10-30 seconds then slowly relax your leg. Bend your knee as much 
as possible and then straighten it. 
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3. Stand in front of a table or chair holding onto it with both hands. 
Slowly crouch keeping your back straight and heels on the floor. Stay down 
for approximately 10-30 seconds and feel the stretching in your buttocks 
and the front of your thighs. 
4. Sitting with your arms crossed.  
Stand up and then sit down slowly on a chair. (This can be made easier by 
using a higher chair, and using your arms to help if you need to. This can 
be made harder by using a lower chair.) 
5. Stand straight. Take a step forwards and take the weight onto the front 
leg. Push off your front leg bringing your legs back together. Repeat with 
the other leg. 
6. Stand in front of a 20 - 40 cm step. 
Step up with one leg leading and then repeat with the other leg leading. 
7. On your bed, lying on your back. Lift your leg towards your chest. Place 
your hands behind the knee. Gently pull your leg towards your chest. Feel 
the stretch behind your thigh. Hold for 10-30 seconds. 
9. Stand on one leg. Try and keep your balance for approximately 10-30 
seconds, or even up to 1 minute if you can. (This can be made easier by 
holding your arms out to the side. This can be made harder by crossing 
your arms, or shutting your eyes.) 
8. On your bed, lying on your side with your legs bent. Take hold of the 
ankle of your upper leg. Gently draw your foot towards your buttock. Feel 
the stretch in the front of your thigh. Hold for 10-30 seconds to the point 
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